Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: Implications for schizophrenia

Biological Psychiatry

Volumn 72, Issue 9, 2012, Pages 785-794

  D'Souza, Deepak Cyril ^a,b,c   Ahn, Kyungheup ^a,b,c   Bhakta, Savita ^a,b,c   Elander, Jacqueline ^a,b,c   Singh, Nagendra ^a,b,c   Nadim, Haleh ^c   Jatlow, Peter ^c   Suckow, Raymond F ^d   Pittman, Brian ^b,c   Ranganathan, Mohini ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University ^*  (United States)

Author keywords

Cognition; glutamate; ketamine; negative symptoms; nicotine; psychosis; schizophrenia

Indexed keywords

KETAMINE; NICOTINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; COGNITIVE DEFECT; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EMOTION; EXECUTIVE FUNCTION; HUMAN; HUMAN EXPERIMENT; INHIBITION (PSYCHOLOGY); LOADING DRUG DOSE; MOTOR PERFORMANCE; NEGATIVE SYNDROME; NORMAL HUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SCHIZOPHRENIA; SMOKING; TASK PERFORMANCE; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; ATTENTION; COGNITION; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EXECUTIVE FUNCTION; HUMANS; INHIBITION (PSYCHOLOGY); KETAMINE; MEMORY; MIDDLE AGED; MOTOR SKILLS; NICOTINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA;

EID: 84867072569     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.05.009     Document Type: Article

References (95)

1. R.W. Heinrichs, K.K. Zakzanis Neurocognitive deficit in schizophrenia: A quantitative review of the evidence Neuropsychology 12 1998 426 445
2. M.F. Green, R.S. Kern, D.L. Braff, J. Mintz Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 26 2000 119 136
3. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 1996 321 330
4. S. Shamsi, A. Lau, T. Lencz, K.E. Burdick, P. DeRosse, R. Brenner Cognitive and symptomatic predictors of functional disability in schizophrenia Schizophr Res 126 2011 257 264
5. H.W. Tsang, A.Y. Leung, R.C. Chung, M. Bell, W.M. Cheung Review on vocational predictors: A systematic review of predictors of vocational outcomes among individuals with schizophrenia: An update since 1998 Aust N Z J Psychiatry 44 2010 495 504
6. R.W. Buchanan, R. Freedman, D.C. Javitt, A. Abi-Dargham, J.A. Lieberman Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia Schizophr Bull 33 2007 1120 1130
7. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, R.P. McMahon The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 2007 1593 1602
8. P.D. Harvey, C.R. Bowie, J.I. Friedman Cognition in schizophrenia Curr Psychiatry Rep 3 2001 423 428
9. T.E. Goldberg, R.D. Greenberg, S.J. Griffin, J.M. Gold, J.E. Kleinman, D. Pickar The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia Br J Psychiatry 162 1993 43 48
10. R.S. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, J.M. Gold Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch Gen Psychiatry 64 2007 633 647
11. H.S. Cho, E.B. Perry, H. Gunduz-Bruce, D.C. D'Souza The ketamine paradigm in humans: Relevance to psychotic disorders U. Heresco-Levy, C. Daniel, D.C. Javitt, Glutamate in Neuropsychiatric Disorders 2008 Research Signpost Trivandrum, Kerala, India 99 131
12. J.T. Kantrowitz, D.C. Javitt N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? Brain Res Bull 83 2010 108 121
13. M.S. D'Souza, A. Markou Schizophrenia and tobacco smoking comorbidity: NAChR agonists in the treatment of schizophrenia-associated cognitive deficits Neuropharmacology 62 2012 1564 1573
14. G.W. Dalack, D.J. Healy, J.H. Meador-Woodruff Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings Am J Psychiatry 155 1998 1490 1501
15. J. de Leon, F.J. Diaz A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors Schizophr Res 76 2005 135 157
16. A. Diwan, M. Castine, C.S. Pomerleau, J.H. Meador-Woodruff, G.W. Dalack Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders Schizophr Res 33 1998 113 118
17. V. Kumari, P. Postma Nicotine use in schizophrenia: The self medication hypotheses Neurosci Biobehav Rev 29 2005 1021 1034
18. D.C. D'Souza, I. Esterlis, M. Carbuto, M. Krasenics, J. Seibyl, F. Bois Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia Am J Psychiatry 169 2012 326 334
19. C. Luckhaus, U. Henning, S. Ferrea, F. Musso, A. Mobascher, G. Winterer Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [(3)H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms J Neural Transm 119 2012 587 595
20. A.A. Patkar, R. Gopalakrishnan, A. Lundy, F.T. Leone, K.M. Certa, S.P. Weinstein Relationship between tobacco smoking and positive and negative symptoms in schizophrenia J Nerv Ment Dis 190 2002 604 610
21. Y.H. Cheng, P. Watts, M. Hinchcliffe, R. Hotchkiss, R. Nankervis, N.F. Faraj Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation J Control Release 79 2002 243 254
22. G.W. Dalack, L. Becks, E. Hill, O.F. Pomerleau, J.H. Meador-Woodruff Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia Neuropsychopharmacology 21 1999 195 202
23. L.E. Adler, L.J. Hoffer, J. Griffith, M.C. Waldo, R. Freedman Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics Biol Psychiatry 32 1992 607 616
24. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review Psychopharmacology (Berl) 156 2001 117 154
25. L.E. Hong, I. Wonodi, J. Lewis, G.K. Thaker Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients Neuropsychopharmacology 33 2008 2167 2174
26. V. Kumari, W. Soni, T. Sharma Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia Hum Psychopharmacol 16 2001 321 326
27. L. Depatie, G.A. O'Driscoll, A.L. Holahan, V. Atkinson, J.X. Thavundayil, N.N. Kin, S. Lal Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study Neuropsychopharmacology 27 2002 1056 1070
28. A.L. Larrison-Faucher, A.A. Matorin, A.B. Sereno Nicotine reduces antisaccade errors in task impaired schizophrenic subjects Prog Neuropsychopharmacol Biol Psychiatry 28 2004 505 516
29. T.P. George, A. Termine, K.A. Sacco, T.M. Allen, E. Reutenauer, J.C. Vessicchio, E.J. Duncan A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: Involvement of nicotinic receptor mechanisms Schizophr Res 87 2006 307 315
30. T.P. George, J.C. Vessicchio, A. Termine, D.M. Sahady, C.A. Head, W.T. Pepper Effects of smoking abstinence on visuospatial working memory function in schizophrenia Neuropsychopharmacology 26 2002 75 85
31. K.A. Sacco, A. Termine, A. Seyal, M.M. Dudas, J.C. Vessicchio, S. Krishnan-Sarin Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms Arch Gen Psychiatry 62 2005 649 659
32. P. Postma, J.A. Gray, T. Sharma, M. Geyer, R. Mehrotra, M. Das A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia Psychopharmacology (Berl) 184 2006 589 599
33. L. Adler, L. Hoffer, A. Wiser, R. Freeman Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am J Psychiatry 150 1993 1856 1861
34. A. Dervaux, X. Laqueille [Smoking and schizophrenia: Epidemiological and clinical features] Encephale 34 2008 299 305
35. L.K. Jacobsen, D.C. D'Souza, W.E. Mencl, K.R. Pugh, P. Skudlarski, J.H. Krystal Nicotine effects on brain function and functional connectivity in schizophrenia Biol Psychiatry 55 2004 850 858
36. C.S. Myers, O. Robles, A.N. Kakoyannis, J.D. Sherr, M.T. Avila, T.A. Blaxton, G.K. Thaker Nicotine improves delayed recognition in schizophrenic patients Psychopharmacology (Berl) 174 2004 334 340
37. D.S. McGehee, M.J. Heath, S. Gelber, P. Devay, L.W. Role Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors Science 269 1995 1692 1696
38. J.A. Dani, M. De Biasi Cellular mechanisms of nicotine addiction Pharmacol Biochem Behav 70 2001 439 446
39. Y. Gioanni, C. Rougeot, P.B. Clarke, C. Lepouse, A.M. Thierry, C. Vidal Nicotinic receptors in the rat prefrontal cortex: Increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission Eur J Neurosci 11 1999 18 30
40. E.K. Lambe, M.R. Picciotto, G.K. Aghajanian Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex Neuropsychopharmacology 28 2003 216 225
41. Y. Fu, S.G. Matta, W. Gao, V.G. Brower, B.M. Sharp Systemic nicotine stimulates dopamine release in nucleus accumbens: Re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area J Pharmacol Exp Ther 294 2000 458 465
42. H.D. Mansvelder, D.S. McGehee Long-term potentiation of excitatory inputs to brain reward areas by nicotine Neuron 27 2000 349 357
43. B. Schilstrom, M.V. Fagerquist, X. Zhang, P. Hertel, G. Panagis, G.G. Nomikos, T.H. Svensson Putative role of presynaptic alpha7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area Synapse 38 2000 375 383
44. B. Schilstrom, G.G. Nomikos, M. Nisell, P. Hertel, T.H. Svensson N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens Neuroscience 82 1998 781 789
45. M.S. Reid, L. Fox, L.B. Ho, S.P. Berger Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: Neuropharmacological characterization Synapse 35 2000 129 136
46. R. Gray, A.S. Rajan, K.A. Radcliffe, M. Yakehiro, J.A. Dani Hippocampal synaptic transmission enhanced by low concentrations of nicotine Nature 383 1996 713 716
47. K.A. Radcliffe, J.L. Fisher, R. Gray, J.A. Dani Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons Ann N Y Acad Sci 868 1999 591 610
48. A.H. Rezvani, E.D. Levin Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats Eur J Pharmacol 465 2003 83 90
49. E. Levin, B. Simon Nicotinic acetylcholine involvement in cognitive function in animals Psychopharmacology (Berl) 138 1998 217 230
50. C. Spielewoy, A. Markou Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: Relevance to smoking in schizophrenia patients Behav Genet 34 2004 343 354
51. O.A. Timofeeva, E.D. Levin Glutamate and nicotinic receptor interactions in working memory: Importance for the cognitive impairment of schizophrenia Neuroscience 195 2011 21 36
52. V.J. Knott, A.M. Millar, J.F. McIntosh, D.K. Shah, D.J. Fisher, C.M. Blais Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention Biol Psychol 88 2011 83 93
53. V. Knott, J. McIntosh, A. Millar, D. Fisher, C. Villeneuve, V. Ilivitsky, E. Horn Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist Pharmacol Biochem Behav 85 2006 228 242
54. M.F. Folstein, S.E. Folstein, P.R. McHugh "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
55. C.R. Clark, R.H. Paul, L.M. Williams, M. Arns, K. Fallahpour, C. Handmer, E. Gordon Standardized assessment of cognitive functioning during development and aging using an automated touchscreen battery Arch Clin Neuropsychol 21 2006 449 467
56. S.M. Silverstein, J. Jaeger, A.M. Donovan-Lepore, S.M. Wilkniss, A. Savitz, I. Malinovsky A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries J Clin Exp Neuropsychol 32 2010 937 952
57. S.R. Kay, L.A. Opler, J.P. Lindenmayer The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation Br J Psychiatry 1989 59 67
58. J.D. Bremner, J.H. Krystal, F.W. Putnam, S.M. Southwick, C. Marmar, D.S. Charney, C.M. Mazure Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) J Trauma Stress 11 1998 125 136
59. L.S. Cox, S.T. Tiffany, A.G. Christen Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings Nicotine Tob Res 3 2001 7 16
60. S.T. Tiffany, D.J. Drobes The development and initial validation of a questionnaire on smoking urges Br J Addict 86 1991 1467 1476
61. J.H. Krystal, E.B. Perry Jr, R. Gueorguieva, A. Belger, S.H. Madonick, A. Abi-Dargham Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch Gen Psychiatry 62 2005 985 994
62. J.K. Staley, S. Krishnan-Sarin, K.P. Cosgrove, E. Krantzler, E. Frohlich, E. Perry Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers J Neurosci 26 2006 8707 8714
63. M. Hariharan, T. VanNoord, J.F. Greden A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma Clin Chem 34 1988 724 729
64. D.C. D'Souza, N. Singh, J. Elander, M. Carbuto, B. Pittman, J.U. de Haes Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence Neuropsychopharmacology 37 2012 1036 1046
65. E. Brunner, S. Domhof, F. Langer Nonparametric Analysis of Longitudinal Data in Factorial Experiments 2002 John Wiley and Sons New York
66. S.B. Floresco, J.D. Jentsch Pharmacological enhancement of memory and executive functioning in laboratory animals Neuropsychopharmacology 36 2011 227 250
67. S.J. Heishman, B.A. Kleykamp, E.G. Singleton Meta-analysis of the acute effects of nicotine and smoking on human performance Psychopharmacology (Berl) 210 2010 453 469
68. A.H. Rezvani, E.D. Levin Cognitive effects of nicotine Biol Psychiatry 49 2001 258 267
69. P. Newhouse, A. Singh, A. Potter Nicotine and nicotinic receptor involvement in neuropsychiatric disorders Curr Top Med Chem 4 2004 267 282
70. B. Froeliger, D.G. Gilbert, F.J. McClernon Effects of nicotine on novelty detection and memory recognition performance: Double-blind, placebo-controlled studies of smokers and nonsmokers Psychopharmacology (Berl) 205 2009 625 633
71. G.E. Swan, C.N. Lessov-Schlaggar The effects of tobacco smoke and nicotine on cognition and the brain Neuropsychol Rev 17 2007 259 273
72. J.A. Pineda, C. Herrera, C. Kang, A. Sandler Effects of cigarette smoking and 12-h abstention on working memory during a serial-probe recognition task Psychopharmacology (Berl) 139 1998 311 321
73. R.A. Rabin, K.A. Sacco, T.P. George Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: Effects of smoking status Schizophr Res 114 2009 91 97
74. N.L. Benowitz, H. Porchet, L. Sheiner, P. Jacob 3rd Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum Clin Pharmacol Ther 44 1988 23 28
75. A. Jackson, J. Nesic, C. Groombridge, O. Clowry, J. Rusted, T. Duka Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking Neuropsychopharmacology 34 2009 257 265
76. L.M. Rowland, L. Beason-Held, C.A. Tamminga, H.H. Holcomb The interactive effects of ketamine and nicotine on human cerebral blood flow Psychopharmacology (Berl) 208 2010 575 584
77. E.D. Levin, C. Bettegowda, T. Weaver, N.C. Christopher Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze Pharmacol Biochem Behav 61 1998 335 340
78. N.R. Mirza, I.P. Stolerman Nicotine enhances sustained attention in the rat under specific task conditions Psychopharmacology (Berl) 138 1998 266 274
79. A.A. Nespor, Y. Tizabi Effects of nicotine on quinpirole- and dizocilpine (MK-801)-induced sensorimotor gating impairments in rats Psychopharmacology (Berl) 200 2008 403 411
80. J.T. Andreasen, K.K. Andersen, E.O. Nielsen, L. Mathiasen, N.R. Mirza Nicotine and clozapine selectively reverse a PCP-induced deficit of PPI in BALB/cByJ but not NMRI mice: Comparison with risperidone Behav Brain Res 167 2006 118 127
81. D. Velligan, R. Brenner, F. Sicuro, D. Walling, R. Riesenberg, A. Sfera Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia Schizophr Res 134 2012 59 64
82. L.E. Hong, G.K. Thaker, R.P. McMahon, A. Summerfelt, J. Rachbeisel, R.L. Fuller Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder Arch Gen Psychiatry 68 2011 1195 1206
83. J.C. Shim, D.U. Jung, S.S. Jung, Y.S. Seo, D.M. Cho, J.H. Lee Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial Neuropsychopharmacology 37 2012 660 668
84. H. Geerts Alpha7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease Expert Opin Investig Drugs 21 2012 59 65
85. R.W. Buchanan, R.R. Conley, D. Dickinson, M.P. Ball, S. Feldman, J.M. Gold, R.P. McMahon Galantamine for the treatment of cognitive impairments in people with schizophrenia Am J Psychiatry 165 2008 82 89
86. M.H. Schubert, K.A. Young, P.B. Hicks Galantamine improves cognition in schizophrenic patients stabilized on risperidone Biol Psychiatry 60 2006 530 533
87. E.L. Ochoa, E. Clark Galantamine may improve attention and speech in schizophrenia Hum Psychopharmacol 21 2006 127 128
88. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch Gen Psychiatry 63 2006 630 638
89. Targacept http://www.drugs.com/clinical-trials/targacept-presents- statistically-significantresults-tc-5619-measures-cognitive-dysfunction-11526. html 2011 Available at
90. M.A. Dyer, O. Freudenreich, M.A. Culhane, G.N. Pachas, T. Deckersbach, E. Murphy High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia Schizophr Res 102 2008 88 95
91. S.W. Lee, J.G. Lee, B.J. Lee, Y.H. Kim A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia Int Clin Psychopharmacol 22 2007 63 68
92. J.P. Lindenmayer, A. Khan Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia Schizophr Res 125 2011 267 277
93. D.L. Kelly, R.P. McMahon, E. Weiner, D.L. Boggs, D. Dickinson, R.R. Conley, R.W. Buchanan Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia Schizophr Res 103 2008 161 168
94. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson Initial phase 2 trial of a nicotinic agonist in schizophrenia Am J Psychiatry 165 2008 1040 1047
95. D. Umbricht, S.R. Murray, D.A. Lowe, G. Garibaldi, K. Yoo, R. Keefe The effect of the partial nicotinic alpha7 receptor agonist R3487 on cognitive deficits in schizophrenia Proceedings from the 48th Annual Meeting of the American College of Neuropsychopharmacology 2009 American College of Neuropsychopharmacology Nashville, TN